| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10909384 | Leukemia Research | 2011 | 5 Pages |
Abstract
Our data indicate that standard doses of rHEPO are at least as effective as higher-doses for correcting anemia in lower-risk MDS patients; in this clinical scenario, this schedule allows for a consistent reduction of costs without precluding the achievement of a durable erythroid response.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Enrico Balleari, Marino Clavio, Eleonora Arboscello, Andrea Bellodi, Andrea Bruzzone, Lisette Del Corso, Maria Vita Lucchetti, Maurizio Miglino, Caterina Passalia, Ivana Pierri, Irene Ponassi, Caterina Oneto, Omar Racchi, Marco Scudeletti, Luana Vignolo,